Passa al contenuto
Merck

Solubilization and humanization of paraoxonase-1.

Journal of lipids (2012-06-22)
Mohosin Sarkar, Christina Keventzidis Harsch, George T Matic, Kathryn Hoffman, Joseph R Norris, Tamara C Otto, David E Lenz, Douglas M Cerasoli, Thomas J Magliery
ABSTRACT

Paraoxonase-1 (PON1) is a serum protein, the activity of which is related to susceptibility to cardiovascular disease and intoxication by organophosphorus (OP) compounds. It may also be involved in innate immunity, and it is a possible lead molecule in the development of a catalytic bioscavenger of OP pesticides and nerve agents. Human PON1 expressed in E. coli is mostly found in the insoluble fraction, which motivated the engineering of soluble variants, such as G2E6, with more than 50 mutations from huPON1. We examined the effect on the solubility, activity, and stability of three sets of mutations designed to solubilize huPON1 with fewer overall changes: deletion of the N-terminal leader, polar mutations in the putative HDL binding site, and selection of the subset of residues that became more polar in going from huPON1 to G2E6. All three sets of mutations increase the solubility of huPON1; the HDL-binding mutant has the largest effect on solubility, but it also decreases the activity and stability the most. Based on the G2E6 polar mutations, we "humanized" an engineered variant of PON1 with high activity against cyclosarin (GF) and found that it was still very active against GF with much greater similarity to the human sequence.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
TERGITOL, Type NP-10